Company news
Biodesix, Inc. news in 2022
Biodesix, Inc.'s news releases, calls and decks from 2022, newest first.
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test
December 18, 2022
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
December 15, 2022
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
November 20, 2022
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
November 16, 2022
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million
November 15, 2022
Biodesix Announces Proposed Public Offering of Common Stock
November 15, 2022
Biodesix Announces Third Quarter 2022 Results and Highlights
November 2, 2022
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
October 19, 2022
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions
October 16, 2022
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
October 11, 2022
Biodesix Announces Preliminary Revenue for Third Quarter 2022
October 10, 2022
Biodesix Named a Top 100 Healthcare Technology Company of 2022
August 8, 2022
Biodesix Announces Second Quarter 2022 Results and Highlights
August 3, 2022
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
July 19, 2022
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
July 18, 2022
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test
June 6, 2022
Biodesix Announces Research Agreement with Top US Cancer Center
June 2, 2022
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
May 11, 2022
Biodesix Announces First Quarter 2022 Results and Highlights
May 10, 2022
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
April 26, 2022
Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer
March 28, 2022
Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights
March 13, 2022
Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital
March 6, 2022
Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer Meeting
March 2, 2022
Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
February 27, 2022
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited)
February 13, 2022
Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results
January 17, 2022
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan
January 3, 2022